EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study

Marina Trivisano iD, Ilaria Mosca, Licia Salimbene, Angela De Dominicis, Paolo Ambrosino, Deborah Puzo, Ilenio Servettini, Cinzia Correale, Chiara Falamesca, Cristina Filosomi, Bianca Goffredo, Maria Virginia Soldovieri iD und 2 weitere

Annals of Neurology · 2025

DOI: 10.1002/ana.27213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, 2025. Verfasst von Marina Trivisano und 13 weiteren Autor:innen. Beteiligte Einrichtung: Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network EpiCARE, Rome, It…. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsies, Partial, Fluoxetine, Nerve Tissue Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry for University and Research, NEXTGENERATIONEU (NGEU), National Recovery and Resilience Plan (NRRP), - A Multiscale integrated approach to the study of the nervous system in health and dise…, NextGenerationEU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Gain‐of‐function (GoF) variants in KCNT1 encoding for potassium channels are associated with different epilepsy phenotypes, including epilepsy of infancy with migrating focal seizures (EIMFS), other early infantile developmental and epileptic encephalopathies, and focal epilepsy. Fluoxetine blocks currents from both wild‐type (WT) and mutant KCNT1 channels with GoF in vitro features. In this study, we tested the hypothesis that treatment with fluoxetine might improve clinical outcome in patients with EIMFS carrying GoF variants in KCNT1 channels showing in vitro sensitivity to fluoxetine blockade.

Methods

We enrolled three pediatric patients carring de novo KCNT1 genetic variants linked to EIMFS. Functional and pharmacological studies to assess fluoxetine's ability to counteract in vitro variant‐induced functional effects were performed with patch‐clamp electrophysiology on heterologous channel expression in mammalian Chinese hamster ovary cells. Neuropsychological assessment, electroencephalogram and seizure diary were evaluated at baseline and every 3 months during the study. Electrocardiography and blood levels of medications were monitored for safety.

Results

All 3 KCNT1 variants displayed GoF effects in vitro. Exposure to fluoxetine (10μM) blocked both WT and mutant KCNT1 channels, therefore, counteracting variant‐induced functional effects. Treatment with fluoxetine caused a variable reduction of seizure frequency (25–75%). Improvement in visual attention, participation, and muscle tone was also reported. No adverse events were reported except for transient dyskinesia in 1 patient, which was probably related to an increase in fluoxetine plasma level.

Interpretation

Fluoxetine may be a potential targeted medication in EIMFS caused by KCNT1 GoF variants. Further research is needed to assess its long‐term efficacy and safety. ANN NEUROL 2025;98:48–61

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsies, PartialFluoxetineNerve Tissue ProteinsPotassium ChannelsSeizuresSelective Serotonin Reuptake InhibitorsAnimalsChild, PreschoolCricetinaeFemaleHumansInfantMaleCHO CellsCricetulusElectroencephalographyGain of Function MutationPotassium Channels, Sodium-Activated

Substanzen

AnticonvulsantsFluoxetineKCNT1 protein, humanNerve Tissue ProteinsPotassium ChannelsSelective Serotonin Reuptake InhibitorsPotassium Channels, Sodium-Activated

Autor:innen und Institutionen

  • Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network EpiCARE, Rome, Italy.
  • Department of Medicine and Health Science "V. Tiberio", University of Molise, Campobasso, Italy.
  • Department of Science and Technology, University of Sannio, Benevento, Italy.
  • Division of Metabolic Diseases and Drug Biology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Department of Neuroscience, Section of Pharmacology, University of Naples "Federico II", Naples, Italy.
  • Department of Development and Regeneration, Catholic University of Leuven, Leuven, Belgium.

ORCID-Profile: Marina Trivisano, Maria Virginia Soldovieri, Maurizio Taglialatela

Förderung

  • Italian Ministry for University and Research
  • NEXTGENERATIONEU (NGEU), National Recovery and Resilience Plan (NRRP), - A Multiscale integrated approach to the study of the nervous system in health and dise…
  • NextGenerationEU

Zitieren

APA

Trivisano, M., Mosca, I., Salimbene, L., De Dominicis, A., Ambrosino, P., Puzo, D., Servettini, I., Correale, C., Falamesca, C., Filosomi, C., Goffredo, B., Soldovieri, M. V., Taglialatela, M., & Specchio, N. (2025). Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study. Annals of Neurology. https://doi.org/10.1002/ana.27213

Vancouver

Trivisano M, Mosca I, Salimbene L, De Dominicis A, Ambrosino P, Puzo D, et al. Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study. Annals of Neurology. 2025. doi:10.1002/ana.27213

BibTeX
@article{Trivisano2025,
  author = {Trivisano, Marina and Mosca, Ilaria and Salimbene, Licia and De Dominicis, Angela and Ambrosino, Paolo and Puzo, Deborah and Servettini, Ilenio and Correale, Cinzia and Falamesca, Chiara and Filosomi, Cristina and Goffredo, Bianca and Soldovieri, Maria Virginia and Taglialatela, Maurizio and Specchio, Nicola},
  title = {Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study},
  journal = {Annals of Neurology},
  year = {2025},
  doi = {10.1002/ana.27213}
}
Kostenlos starten →